Minimal Change Disease (MCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Minimal Change Disease (MCD) is a kidney disorder characterized by significant protein loss in the urine, making it one of the primary causes of Nephrotic Syndrome. Edema, notably swelling in the feet and legs that may extend to the hips and abdomen, is a prominent symptom. MCD typically presents a favorable prognosis, particularly in children, where it constitutes the most common cause of idiopathic nephrotic syndrome. Among children aged over one year with nephrotic syndrome, MCD accounts for 70% to 90% of cases, compared to only 10-15% in adults. The initial manifestation of MCD is nephrotic syndrome, marked by increased permeability of the renal membrane leading to significant protein loss, primarily albumin, due to impairment of the glomerular filtration barrier (GFB). The GFB comprises the glomerular basement membrane, the endothelium forming the inner layer, and the outer epithelial layer consisting of podocytes, specialized epithelial cells characterized by elongated foot processes, and large cell bodies running parallel to the glomerular capillary wall. Slit diaphragms, cell-to-cell connections, are located between podocyte foot processes. Steroids represent the primary treatment for MCD. Children typically achieve remission within four weeks of steroid therapy, while adults may require two months or longer. Relapse is common in both age groups. For children, prednisone therapy typically begins at 60 mg/m^2 (or 2 mg/kg) administered daily for 4-6 weeks (maximum dose: 60 mg/day), or 40 mg/m^2 (or 1.5 mg/kg) given on alternate days for a taper period of 2–5 months. A gradual reduction in dosage by 5 mg/m^2 to 10 mg/m^2 per week is recommended for at least 12 weeks, with an additional four weeks before discontinuation. Adults are usually prescribed 1 mg/kg or 2 mg/kg every other day for the initial 4–16 weeks (maximum 80 mg/day or 120 mg every other day). Dosage should be gradually tapered over six months.

Thelansis’s “Minimal Change Disease (MCD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Minimal Change Disease (MCD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Minimal Change Disease (MCD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Minimal Change Disease (MCD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Minimal Change Disease (MCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033